RFG Advisory LLC Buys Shares of 6,410 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RFG Advisory LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,410 shares of the company's stock, valued at approximately $2,692,000.

Other large investors have also recently bought and sold shares of the company. United Capital Financial Advisors LLC increased its holdings in shares of IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after acquiring an additional 22 shares during the last quarter. Gabelli Funds LLC raised its holdings in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares in the last quarter. Summit Trail Advisors LLC lifted its position in shares of IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after buying an additional 26 shares during the last quarter. Forum Financial Management LP boosted its holdings in shares of IDEXX Laboratories by 4.9% in the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after buying an additional 29 shares in the last quarter. Finally, Retirement Wealth Solutions LLC boosted its holdings in shares of IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded up $2.48 during mid-day trading on Friday, hitting $524.69. The stock had a trading volume of 132,339 shares, compared to its average volume of 649,515. The firm has a market cap of $42.20 billion, a PE ratio of 49.21, a PEG ratio of 3.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.73. The company's 50-day simple moving average is $458.03 and its 200-day simple moving average is $439.98. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the firm earned $2.71 EPS. The business's revenue was up 3.6% on a year-over-year basis. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.98% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.